Combination Therapy and Payer Perspective on CKD Therapies
Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.
Using Published Data to Consider SGLT2 Inhibitors and MRAs in CKD Management
Dr Jeffrey Feldman discusses finerenone trial data and the role that it and SGLT2 inhibitors have played in patients with CKD.
Utilizing Pirfenidone in ILD Treatment Strategy
Dr Noble discusses recent ATS guidelines regarding the use of pirfenidone in ILD.
FDA-Approved Treatment Options for ILD
ILD treatment options approved by the FDA are explored by Dr Noble, MD.
MDS Impacting Patient Quality of Life
Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.
Defining Myelodysplastic Syndrome
A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).
Role of JAK Inhibitors in Treatment of Vitiligo
Dr Rosmarin illustrates treatment management of vitiligo with the use of JAK inhibitors.
Unmet Needs in Vitiligo Treatment Landscape
The panel navigates unmet needs surrounding the vitiligo treatment landscape.
Identifying Unmet Needs Surrounding Patients With Heart Failure
The panel of experts provide their final insights regarding unmet needs surrounding treatment management of heart failure.
Patient and Provider Perceptions Surrounding Affordability for HF Treatments
Experts share their thoughts on payer and provider perceptions surrounding affordable HF care, as well as strategies to manage care-associated costs.
Navigating Multidisciplinary HF Treatment With Multiple Comorbidities
Multiple comorbidities lead to an emphasis on multidisciplinary care management when determining the most effective HF treatment strategies.
Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data
IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
Gaining Confidence With a Switching Study
Sonia T. Oskouei, PharmD, BCMAS, DPLA, navigates the impact of the VOLTAIRE-X study, the only published switching study for adalimumab, on biosimilar uptake.
Treatment Landscape Surrounding Anti-Fibrotic Agents
Dr Noble, MD provides and overview of the treatment landscape surrounding ILD, specifically examining IPF, PPF, and SSc-ILD antifibrotic therapy.
ATS Guideline Updates in Treatment Paradigms for ILD
Dr Paul Noble, MD discusses updates and changes in ATS-directed guidelines for the treatment of ILD.
The Role of MRAs in CKD and CV Treatment
Dr Agarwal provides a deep dive into the use of nonsteroidal mineralocorticoid receptor antagonists in CKD therapy.
Treating CKD Using Multiple Methods
Dr Feldman concludes the treatment landscape overview by discussing glycemic control, SGLT2 inhibitors, and other important management techniques.
IMpower010 Trial Evaluating Atezolizumab Versus Best Supportive Care (BSC)
Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).
Future Opportunities to Improve PrEP Access and Management
Carl Schmid and Lynne H. Milgram, MD, MBA, CPE, conclude with sharing ideas that can provide more substantial access to PrEP and battle unmet needs in PrEP management.
Enhancing Patient Education on PrEP Therapies
Drs Palella Jr and Milgram explains the disconnect between PrEP and patient education and comments on how to fix it.
The Social Determinants Affecting PrEP Use and Access
Carl Schmid and Dr Milgram discusses the disparities in education and access to PrEP in the patient populations that need these medications the most.
Improving HF Population Health Management and Collaborative Care
Dr Uppal outlines population health management strategies directed to improve access to care and treatment management for patients with heart failure.
Cost-Saving Strategies Through PCP-Prescribed Therapies in HF
Dr Murillo navigates cost-saving strategies for heart failure treatment by emphasizing collaborative care between specialists and frontline primacy care teams.
Aligning Payer and Provider Considerations
Navigating payer and provider considerations to ensure optimal care management for vitiligo.
Optimal Therapies for Treating Vitiligo
A variety of treatment options for vitiligo are explored by Drs Dunn, Rosmarin, and King.
Blood Pressure Management Within the CKD Treatment Landscape
Drs Agarwal and Pitt begin an overview of the CKD treatment landscape, beginning with the importance of blood pressure management.
Treatment Goals for Patients With CKD
Jeffrey Feldman, MD, describes the treatment goals for patients with CKD.
Receiving Grade A Recommendations for Injectable PrEP and New Agents
Lynne H. Milgram, MD, MBA, CPE, speaks about the USPSTF Grade A recommendation for injectable cabotegravir and how it could affect emerging agents in the future.
Utilizing Data for Policies and Cost-Effectiveness of PrEP Agents
Dr Milgram focuses on the cost-effectiveness of cabotegravir as a long-acting injectable PrEP therapy and how providers and payers use data and real-world evidence to create PrEP policies.
SGLT2 Inhibitor Impact on Hospitalization Reduction and HF Disease Progression
The impact of SGLT2 inhibitors in heart failure treatment is highlighted by the EMPEROR-Preserved and EMPEROR-Reduced trials.
